⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
Form 8-K
sec.gov
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K/A
sec.gov
OSTX